These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 39028664)

  • 1. Reduced Likelihood of Hospitalization With the JN.1 or HV.1 Severe Acute Respiratory Syndrome Coronavirus 2 Variants Compared With the EG.5 Variant.
    Levy ME; Chilunda V; Davis RE; Heaton PR; Pawloski PA; Goldman JD; Schandl CA; McEwen LM; Cirulli ET; Wyman D; Rossi AD; Dai H; Isaksson M; Washington NL; Basler T; Tsan K; Nguyen J; Ramirez J; Sandoval E; Lee W; Lu J; Luo S
    J Infect Dis; 2024 Nov; 230(5):1197-1201. PubMed ID: 39028664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omicron variants of SARS-CoV-2: Epidemiological and clinical insights from a tertiary care center in Saudi Arabia.
    Dubaie B; Aldayel A; Alwethinani S; Alhuthil R; Alhamlan F; Alghamdi S; Alsuhaibani M; Aljumaah S; AlYabes O; AlBanyan E; Al-Hajjar S
    J Infect Public Health; 2024 Jun; 17(6):961-966. PubMed ID: 38608457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.
    Moustsen-Helms IR; Bager P; Larsen TG; Møller FT; Vestergaard LS; Rasmussen M; Hansen CH;
    Lancet Infect Dis; 2024 Sep; 24(9):964-973. PubMed ID: 38761806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron XBB and JN.1 Lineages - United States, May 2023-September 2024.
    Ma KC; Castro J; Lambrou AS; Rose EB; Cook PW; Batra D; Cubenas C; Hughes LJ; MacCannell DR; Mandal P; Mittal N; Sheth M; Smith C; Winn A; Hall AJ; Wentworth DE; Silk BJ; Thornburg NJ; Paden CR
    MMWR Morb Mortal Wkly Rep; 2024 Oct; 73(42):938-945. PubMed ID: 39446667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage.
    Lewnard JA; Mahale P; Malden D; Hong V; Ackerson BK; Lewin BJ; Link-Gelles R; Feldstein LR; Lipsitch M; Tartof SY
    Nat Commun; 2024 Oct; 15(1):8550. PubMed ID: 39362845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024.
    Ma KC; Surie D; Lauring AS; Martin ET; Leis AM; Papalambros L; Gaglani M; Columbus C; Gottlieb RL; Ghamande S; Peltan ID; Brown SM; Ginde AA; Mohr NM; Gibbs KW; Hager DN; Saeed S; Prekker ME; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Khan A; Hough CL; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Kwon JH; Parikh B; Exline MC; Vaughn IA; Ramesh M; Safdar B; Mosier J; Harris ES; Shapiro NI; Felzer J; Zhu Y; Grijalva CG; Halasa N; Chappell JD; Womack KN; Rhoads JP; Baughman A; Swan SA; Johnson CA; Rice TW; Casey JD; Blair PW; Han JH; Ellington S; Lewis NM; Thornburg N; Paden CR; Atherton LJ; Self WH; Dawood FS; DeCuir J
    Clin Infect Dis; 2024 Aug; ():. PubMed ID: 39107255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spike structures, receptor binding, and immune escape of recently circulating SARS-CoV-2 Omicron BA.2.86, JN.1, EG.5, EG.5.1, and HV.1 sub-variants.
    Li L; Shi K; Gu Y; Xu Z; Shu C; Li D; Sun J; Cong M; Li X; Zhao X; Yu G; Hu S; Tan H; Qi J; Ma X; Liu K; Gao GF
    Structure; 2024 Aug; 32(8):1055-1067.e6. PubMed ID: 39013463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity - IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024.
    Ma KC; Surie D; Lauring AS; Martin ET; Leis AM; Papalambros L; Gaglani M; Columbus C; Gottlieb RL; Ghamande S; Peltan ID; Brown SM; Ginde AA; Mohr NM; Gibbs KW; Hager DN; Saeed S; Prekker ME; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Khan A; Hough CL; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Kwon JH; Parikh B; Exline MC; Vaughn IA; Ramesh M; Safdar B; Mosier J; Harris ES; Shapiro NI; Felzer J; Zhu Y; Grijalva CG; Halasa N; Chappell JD; Womack KN; Rhoads JP; Baughman A; Swan SA; Johnson CA; Rice TW; Casey JD; Blair PW; Han JH; Ellington S; Lewis NM; Thornburg N; Paden CR; Atherton LJ; Self WH; Dawood FS; DeCuir J
    medRxiv; 2024 Jun; ():. PubMed ID: 38883802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.
    Chalkias S; McGhee N; Whatley JL; Essink B; Brosz A; Tomassini JE; Girard B; Edwards DK; Wu K; Nasir A; Lee D; Avena LE; Feng J; Deng W; Montefiori DC; Baden LR; Miller JM; Das R
    J Infect Dis; 2024 Aug; 230(2):e279-e286. PubMed ID: 38349280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1.
    Wang W; Bhushan G; Paz S; Stauft CB; Selvaraj P; Goguet E; Bishop-Lilly KA; Subramanian R; Vassell R; Lusvarghi S; Cong Y; Agan B; Richard SA; Epsi NJ; Fries A; Fung CK; Conte MA; Holbrook MR; Wang TT; Burgess TH; Pollett SD; Mitre E; Katzelnick LC; Weiss CD
    J Virol; 2024 Nov; 98(11):e0094824. PubMed ID: 39365051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.
    Soudani N; Bricker TL; Darling T; Seehra K; Patel N; Guebre-Xabier M; Smith G; Davis-Gardner M; Suthar MS; Ellebedy AH; Boon ACM
    J Virol; 2024 Oct; 98(10):e0052824. PubMed ID: 39230305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory virus disease and outcomes at a large academic medical center in the United States: a retrospective observational study of the early 2023/2024 respiratory viral season.
    Mostafa HH; Fall A; Norton JM; Sachithanandham J; Yunker M; Abdullah O; Hanlon A; Gluck L; Morris CP; Pekosz A; Klein EY
    Microbiol Spectr; 2024 Oct; 12(10):e0111624. PubMed ID: 39162510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes in COVID-19 patients infected with different SARS-CoV-2 variants in Marseille, France.
    Dao TL; Hoang VT; Nguyen NN; Delerce J; Chaudet H; Levasseur A; Lagier JC; Raoult D; Colson P; Gautret P
    Clin Microbiol Infect; 2021 Oct; 27(10):1516.e1-1516.e6. PubMed ID: 34044152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JN.1 variant in enduring COVID-19 pandemic: is it a variety of interest (VoI) or variety of concern (VoC)?
    Kamble P; Daulatabad V; Singhal A; Ahmed ZS; Choubey A; Bhargava S; John NA
    Horm Mol Biol Clin Investig; 2024 Jun; 45(2):49-53. PubMed ID: 38622986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Risk of Hospitalization and Severe Disease Among Co-circulating Severe Acute Respiratory Syndrome Coronavirus 2 Variants.
    Trobajo-Sanmartín C; Miqueleiz A; Guevara M; Fernández-Huerta M; Burgui C; Casado I; Baigorria F; Navascués A; Ezpeleta C; Castilla J
    J Infect Dis; 2023 Feb; 227(3):332-338. PubMed ID: 36179126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies.
    He Q; An Y; Zhou X; Xie H; Tao L; Li D; Zheng A; Li L; Xu Z; Yu S; Wang R; Hu H; Liu K; Wang Q; Dai L; Xu K; Gao GF
    Med; 2024 May; 5(5):401-413.e4. PubMed ID: 38574739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Factors for Severe COVID-19 Among Children and Adolescents Enrolled in Acute Respiratory Infection Sentinel Surveillance in South Africa, 2020-2022.
    Bishop K; Meiring S; Tempia S; von Gottberg A; Wolter N; Kleynhans J; Moosa F; du Plessis M; Moyes J; Makhasi M; Chuene B; Samuels AM; Dawood H; Reubenson G; Zar HJ; Quan V; Cohen C; Walaza S
    Influenza Other Respir Viruses; 2024 May; 18(5):e13300. PubMed ID: 38666359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection.
    Springer DN; Camp JV; Aberle SW; Deutsch J; Lammel O; Weseslindtner L; Stiasny K; Aberle JH
    J Med Virol; 2024 Jul; 96(7):e29801. PubMed ID: 38988204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage.
    Lewnard JA; Mahale P; Malden D; Hong V; Ackerson BK; Lewin BJ; Link-Gelles R; Feldstein LR; Lipsitch M; Tartof SY
    medRxiv; 2024 Apr; ():. PubMed ID: 38699313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
    Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
    mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.